



COPY OF PAPERS
ORIGINALLY FILED

1109

#10/K.T.
9/8
1653 Pre
A

Docket No. 13761-7024

TECH CENTER 1600/2900

JUN 03 2002

RECEIVED

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ a.m./p.m.

Dated: May 20, 2002

Name of Person Certifying: *John M. Barrett*

Printed Name: *John M. Barrett*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lin, et al.

Assignee: University of Southern California

Filing Date: 08/01/2001

Examiner: Unassigned

Serial No.: 09/920,342

Group Art Unit: 1653

Title: **GENE SILENCING USING mRNA-CDNA HYBRIDS**

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please enter the following Preliminary Amendment in the above-identified patent application.

IN THE CLAIMS

Please ADD the following new dependent claims:

46. (New) The method of claim 19, wherein the nucleotide analog is selected from the group consisting of uracil, inosine, xanthine, hypoxanthine, labeled nucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphothio-linked nucleotide, morpholino nucleotide and peptide nucleic acid (PNA).

47. (New) The method of claim 19, wherein the nucleotide analog is a ribonucleotide.

48. (New) The method of claim 19, wherein the nucleotide analog is a deoxyribonucleotide.